The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials

Recent evidence shows that moxifloxacin could exert an antimicrobial effect against Helicobacter pylori in both in vitroand in vivo models. To systematically evaluate whether moxifloxacin-containing triple therapy could improve eradication rates and reduce side effects in first-line or second-line anti-H. pyloritreatment, eligible articles were identified by searches of electronic databases. We included all randomized trials comparing moxifloxacin-based triple therapy with standard triple or quadruple therapy during H. pylori eradication treatment. Statistical analysis was performed with Review Manager 5.0.10. Subanalysis/sensitivity analysis was also performed. We identified seven randomized trials (n=1263). Pooled H. pylori eradication rates were 79.03% (95%CI: 75.73-82.07) and 68.33% (95%CI: 64.44-72.04) for patients with moxifloxacin-based triple therapy or with standard triple or quadruple therapy, respectively (intention-to-treat analysis). The odds ratio (OR) was 1.82 (95%CI: 1.17-2.81), the occurrence of total side effects was 15.23% (95%CI: 12.58-18.20) and 27.17% (95%CI: 23.64-30.92) for groups with or without moxifloxacin, and the summary OR was 0.45 (95%CI: 0.26-0.77). In subgroup analyses, we noted that the second-line eradication rate in the moxifloxacin group was significantly higher than that in the quadruple therapy group (73.33 vs 60.17%, OR: 1.78, 95%CI: 1.16-2.73, P<0.001). However, there was no difference in first-line eradication treatment. Findings from this meta-analysis suggest that moxifloxacin-based triple therapy is more effective and better tolerated than standard triple or quadruple therapy. Therefore, a moxifloxacin-based triple regimen should be used in the second-line treatment of H. pylori infection.

Saved in:
Bibliographic Details
Main Authors: Zhang,G., Zou,J., Liu,F., Bao,Z., Dong,F., Huang,Y., Yin,S.
Format: Digital revista
Language:English
Published: Associação Brasileira de Divulgação Científica 2013
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2013000700607
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0100-879X2013000700607
record_format ojs
spelling oai:scielo:S0100-879X20130007006072015-10-19The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trialsZhang,G.Zou,J.Liu,F.Bao,Z.Dong,F.Huang,Y.Yin,S. Moxifloxacin Helicobacter pylori Eradication rate Side effects Meta-analysis Recent evidence shows that moxifloxacin could exert an antimicrobial effect against Helicobacter pylori in both in vitroand in vivo models. To systematically evaluate whether moxifloxacin-containing triple therapy could improve eradication rates and reduce side effects in first-line or second-line anti-H. pyloritreatment, eligible articles were identified by searches of electronic databases. We included all randomized trials comparing moxifloxacin-based triple therapy with standard triple or quadruple therapy during H. pylori eradication treatment. Statistical analysis was performed with Review Manager 5.0.10. Subanalysis/sensitivity analysis was also performed. We identified seven randomized trials (n=1263). Pooled H. pylori eradication rates were 79.03% (95%CI: 75.73-82.07) and 68.33% (95%CI: 64.44-72.04) for patients with moxifloxacin-based triple therapy or with standard triple or quadruple therapy, respectively (intention-to-treat analysis). The odds ratio (OR) was 1.82 (95%CI: 1.17-2.81), the occurrence of total side effects was 15.23% (95%CI: 12.58-18.20) and 27.17% (95%CI: 23.64-30.92) for groups with or without moxifloxacin, and the summary OR was 0.45 (95%CI: 0.26-0.77). In subgroup analyses, we noted that the second-line eradication rate in the moxifloxacin group was significantly higher than that in the quadruple therapy group (73.33 vs 60.17%, OR: 1.78, 95%CI: 1.16-2.73, P<0.001). However, there was no difference in first-line eradication treatment. Findings from this meta-analysis suggest that moxifloxacin-based triple therapy is more effective and better tolerated than standard triple or quadruple therapy. Therefore, a moxifloxacin-based triple regimen should be used in the second-line treatment of H. pylori infection.info:eu-repo/semantics/openAccessAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research v.46 n.7 20132013-07-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2013000700607en10.1590/1414-431X20132817
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Zhang,G.
Zou,J.
Liu,F.
Bao,Z.
Dong,F.
Huang,Y.
Yin,S.
spellingShingle Zhang,G.
Zou,J.
Liu,F.
Bao,Z.
Dong,F.
Huang,Y.
Yin,S.
The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials
author_facet Zhang,G.
Zou,J.
Liu,F.
Bao,Z.
Dong,F.
Huang,Y.
Yin,S.
author_sort Zhang,G.
title The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials
title_short The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials
title_full The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials
title_fullStr The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials
title_full_unstemmed The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials
title_sort efficacy of moxifloxacin-based triple therapy in treatment of helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials
description Recent evidence shows that moxifloxacin could exert an antimicrobial effect against Helicobacter pylori in both in vitroand in vivo models. To systematically evaluate whether moxifloxacin-containing triple therapy could improve eradication rates and reduce side effects in first-line or second-line anti-H. pyloritreatment, eligible articles were identified by searches of electronic databases. We included all randomized trials comparing moxifloxacin-based triple therapy with standard triple or quadruple therapy during H. pylori eradication treatment. Statistical analysis was performed with Review Manager 5.0.10. Subanalysis/sensitivity analysis was also performed. We identified seven randomized trials (n=1263). Pooled H. pylori eradication rates were 79.03% (95%CI: 75.73-82.07) and 68.33% (95%CI: 64.44-72.04) for patients with moxifloxacin-based triple therapy or with standard triple or quadruple therapy, respectively (intention-to-treat analysis). The odds ratio (OR) was 1.82 (95%CI: 1.17-2.81), the occurrence of total side effects was 15.23% (95%CI: 12.58-18.20) and 27.17% (95%CI: 23.64-30.92) for groups with or without moxifloxacin, and the summary OR was 0.45 (95%CI: 0.26-0.77). In subgroup analyses, we noted that the second-line eradication rate in the moxifloxacin group was significantly higher than that in the quadruple therapy group (73.33 vs 60.17%, OR: 1.78, 95%CI: 1.16-2.73, P<0.001). However, there was no difference in first-line eradication treatment. Findings from this meta-analysis suggest that moxifloxacin-based triple therapy is more effective and better tolerated than standard triple or quadruple therapy. Therefore, a moxifloxacin-based triple regimen should be used in the second-line treatment of H. pylori infection.
publisher Associação Brasileira de Divulgação Científica
publishDate 2013
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2013000700607
work_keys_str_mv AT zhangg theefficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT zouj theefficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT liuf theefficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT baoz theefficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT dongf theefficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT huangy theefficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT yins theefficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT zhangg efficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT zouj efficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT liuf efficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT baoz efficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT dongf efficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT huangy efficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT yins efficacyofmoxifloxacinbasedtripletherapyintreatmentofhelicobacterpyloriinfectionasystematicreviewandmetaanalysisofrandomizedclinicaltrials
_version_ 1756391426764046336